Van Lanschot Kempen Investment Management N.V. Lowers Holdings in Kenvue Inc. $KVUE

Key Points

Error: Response status code does not indicate success: 429 (Too Many Requests).

Van Lanschot Kempen Investment Management N.V. lowered its position in Kenvue Inc. (NYSE:KVUE - Free Report) by 42.4% in the first quarter, according to the company in its most recent disclosure with the SEC. The firm owned 780,003 shares of the company's stock after selling 573,593 shares during the period. Van Lanschot Kempen Investment Management N.V.'s holdings in Kenvue were worth $18,704,000 at the end of the most recent quarter.

A number of other large investors have also modified their holdings of the company. Pittenger & Anderson Inc. acquired a new stake in Kenvue in the 1st quarter worth about $30,000. TruNorth Capital Management LLC purchased a new stake in Kenvue during the 1st quarter worth approximately $36,000. Clal Insurance Enterprises Holdings Ltd increased its stake in Kenvue by 378.5% during the 1st quarter. Clal Insurance Enterprises Holdings Ltd now owns 1,627 shares of the company's stock worth $39,000 after buying an additional 1,287 shares in the last quarter. Bank Julius Baer & Co. Ltd Zurich increased its stake in Kenvue by 120.6% during the 1st quarter. Bank Julius Baer & Co. Ltd Zurich now owns 1,699 shares of the company's stock worth $41,000 after buying an additional 929 shares in the last quarter. Finally, Continuum Advisory LLC increased its stake in Kenvue by 2,071.1% during the 1st quarter. Continuum Advisory LLC now owns 1,954 shares of the company's stock worth $47,000 after buying an additional 1,864 shares in the last quarter. Institutional investors and hedge funds own 97.64% of the company's stock.

Analysts Set New Price Targets

KVUE has been the subject of several research reports. Zacks Research upgraded Kenvue to a "strong sell" rating in a research note on Monday, August 11th. Bank of America cut their price objective on Kenvue from $27.00 to $25.00 and set a "buy" rating for the company in a research note on Tuesday, July 15th. Canaccord Genuity Group cut their price objective on Kenvue from $29.00 to $26.00 and set a "buy" rating for the company in a research note on Friday, August 8th. JPMorgan Chase & Co. cut their price objective on Kenvue from $27.00 to $26.00 and set an "overweight" rating for the company in a research note on Friday, July 25th. Finally, Royal Bank Of Canada decreased their target price on shares of Kenvue from $24.00 to $22.00 and set a "sector perform" rating on the stock in a research note on Friday, August 8th. Five analysts have rated the stock with a Buy rating, seven have assigned a Hold rating and one has given a Sell rating to the company. According to data from MarketBeat.com, the stock currently has an average rating of "Hold" and a consensus price target of $24.38.

Kenvue Price Performance

KVUE traded up $0.1550 during trading on Friday, reaching $21.5950. The company's stock had a trading volume of 8,620,226 shares, compared to its average volume of 18,631,350. The company has a quick ratio of 0.68, a current ratio of 0.98 and a debt-to-equity ratio of 0.66. The firm has a fifty day simple moving average of $21.52 and a two-hundred day simple moving average of $22.42. Kenvue Inc. has a 1 year low of $19.75 and a 1 year high of $25.17. The company has a market cap of $41.44 billion, a price-to-earnings ratio of 29.18, a PEG ratio of 3.08 and a beta of 0.83.

Kenvue (NYSE:KVUE - Get Free Report) last released its earnings results on Thursday, August 7th. The company reported $0.29 earnings per share for the quarter, topping analysts' consensus estimates of $0.28 by $0.01. Kenvue had a net margin of 9.37% and a return on equity of 20.06%. The business had revenue of $3.84 billion for the quarter, compared to analyst estimates of $3.94 billion. During the same period last year, the company posted $0.32 EPS. The business's revenue was down 4.0% on a year-over-year basis. Kenvue has set its FY 2025 guidance at 1.000-1.050 EPS. As a group, analysts anticipate that Kenvue Inc. will post 1.14 EPS for the current year.

Kenvue Increases Dividend

The firm also recently disclosed a quarterly dividend, which will be paid on Wednesday, August 27th. Investors of record on Wednesday, August 13th will be given a $0.2075 dividend. The ex-dividend date is Wednesday, August 13th. This is a positive change from Kenvue's previous quarterly dividend of $0.21. This represents a $0.83 annualized dividend and a yield of 3.8%. Kenvue's dividend payout ratio (DPR) is currently 112.16%.

Kenvue Company Profile

Kenvue Inc operates as a consumer health company worldwide. The company operates through three segments: Self Care, Skin Health and Beauty, and Essential Health. The Self Care segment offers cough, cold and allergy, pain care, digestive health, smoking cessation, eye care, and other products under the Tylenol, Motrin, Benadryl, Nicorette, Zarbee's, ORSLTM, Rhinocort, Calpol, and Zyrtec brands.